Japan's small supermarkets outpace bigger rivals amid rising prices
** Japanese supermarket chain operators Trial Holdings 141A.T and Genky Drugstores 9267.T outperform their bigger rivals this year as investors bet on their ability to offer low prices amid rising inflation
** Besides their cheap but quality prepared meals, the duo also benefit from lower labor costs in regional cities, says Zentaro Yamada, analyst at Tachibana Securities
** Trial Holdings has surged 48% since its March IPO, with most gains since early Aug after it posted 37% jump in FY annual operating profit
** Genky, a drug store chain operator that focuses on fresh food and prepared meals, has risen 40% this year, with most gains since late July after it posted a 34% jump in FY operating profit
** Meanwhile, their bigger rivals Aeon 8267.T and Life 8194.T have risen 18% and 8%, respectively, this year
** Retail giant Seven & i Holdings 3382.T has closed some Ito-Yokado supermarkets and is set to close more outlets as they struggle to compete with specialty outlets and discount stores
Reporting by Junko Fujita
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
